These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 33830457)

  • 21. Timing and course of clinical response to intravenous immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy.
    Latov N; Deng C; Dalakas MC; Bril V; Donofrio P; Hanna K; Hartung HP; Hughes RA; Merkies IS; van Doorn PA;
    Arch Neurol; 2010 Jul; 67(7):802-7. PubMed ID: 20457948
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In persons with CIDP, auto-HSCT can be conducted fully on an outpatient basis and induces significant clinical responses: A prospective study in a single center.
    Montes-Robles MA; Gallardo-Pérez MM; Hernández-Flores EJ; Pastelín-Martínez ML; Sánchez-Bonilla D; Robles-Nasta M; Ocaña-Ramm G; Olivares-Gazca JC; Ruiz-Delgado GJ; Ruiz-Argüelles GJ
    Transpl Immunol; 2023 Dec; 81():101944. PubMed ID: 37866669
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Assessment timing and choice of outcome measure in determining treatment response in chronic inflammatory demyelinating polyneuropathy: A post hoc analysis of the PRISM trial.
    Rajabally YA; Ouaja R; Kasiborski F; Pujol S; Nobile-Orazio E
    Muscle Nerve; 2022 Nov; 66(5):562-567. PubMed ID: 36057106
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical-neurophysiological correlations in chronic inflammatory demyelinating polyradiculoneuropathy patients treated with subcutaneous immunoglobulin.
    Cirillo G; Todisco V; Ricciardi D; Tedeschi G
    Muscle Nerve; 2019 Dec; 60(6):662-667. PubMed ID: 31415091
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Quantitative grip force assessment of muscular weakness in chronic inflammatory demyelinating polyneuropathy.
    Klehmet J; Beutner S; Hoffmann S; Dornauer M; Paul F; Reilmann R; Brandt AU; Meisel A
    BMC Neurol; 2019 Jun; 19(1):118. PubMed ID: 31176377
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effectiveness and safety of rituximab in autoimmune nodopathy: a single-center cohort study.
    Liu B; Hu J; Sun C; Qiao K; Xi J; Zheng Y; Sun J; Luo S; Zhao Y; Lu J; Lin J; Zhao C
    J Neurol; 2023 Sep; 270(9):4288-4295. PubMed ID: 37195346
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatments for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): an overview of systematic reviews.
    Oaklander AL; Lunn MP; Hughes RA; van Schaik IN; Frost C; Chalk CH
    Cochrane Database Syst Rev; 2017 Jan; 1(1):CD010369. PubMed ID: 28084646
    [TBL] [Abstract][Full Text] [Related]  

  • 28. An international multicenter efficacy and safety study of IqYmune in initial and maintenance treatment of patients with chronic inflammatory demyelinating polyradiculoneuropathy: PRISM study.
    Nobile-Orazio E; Pujol S; Kasiborski F; Ouaja R; Corte GD; Bonek R; Cocito D; Schenone A
    J Peripher Nerv Syst; 2020 Dec; 25(4):356-365. PubMed ID: 32808406
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of subcutaneous immunoglobulin on quality of life in patients with chronic inflammatory demyelinating polyneuropathy previously treated with intravenous immunoglobulin.
    Vu T; Anthony N; Alsina R; Harvey B; Schleutker A; Farias J; Dang S; Suresh N; Gooch C
    Muscle Nerve; 2021 Sep; 64(3):351-357. PubMed ID: 34076265
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Vigorimeter grip strength in CIDP: a responsive tool that rapidly measures the effect of IVIG--the ICE study.
    Vanhoutte EK; Latov N; Deng C; Hanna K; Hughes RA; Bril V; Dalakas MC; Donofrio P; van Doorn PA; Hartung HP; Merkies IS
    Eur J Neurol; 2013 May; 20(5):748-55. PubMed ID: 22891893
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Quality of life in patients with multifocal motor neuropathy from Serbia.
    Bozovic I; Peric S; Basta I; Kacar A; Nikolic A; Belanovic B; Lavrnic D; Rakocevic-Stojanovic V; Stevic Z
    J Neurol Sci; 2019 Apr; 399():151-154. PubMed ID: 30818075
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy of rituximab treatment in chronic inflammatory demyelinating polyradiculoneuropathy: a systematic review and meta-analysis.
    Hu J; Sun C; Lu J; Zhao C; Lin J
    J Neurol; 2022 Mar; 269(3):1250-1263. PubMed ID: 34120208
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Changing outcome in inflammatory neuropathies: Rasch-comparative responsiveness.
    Draak TH; Vanhoutte EK; van Nes SI; Gorson KC; Van der Pol WL; Notermans NC; Nobile-Orazio E; Léger JM; Van den Bergh PY; Lauria G; Bril V; Katzberg H; Lunn MP; Pouget J; van der Kooi AJ; Hahn AF; Doorn PA; Cornblath DR; van den Berg LH; Faber CG; Merkies IS;
    Neurology; 2014 Dec; 83(23):2124-32. PubMed ID: 25378677
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Quality of life in inflammatory neuropathies: the IN-QoL.
    Draak THP; Faber CG; Merkies ISJ;
    J Neurol Neurosurg Psychiatry; 2018 Mar; 89(3):256-262. PubMed ID: 28986470
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term neurophysiological and clinical response in patients with chronic inflammatory demyelinating polyradiculoneuropathy treated with subcutaneous immunoglobulin.
    Cirillo G; Todisco V; Tedeschi G
    Clin Neurophysiol; 2018 May; 129(5):967-973. PubMed ID: 29554579
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Predicting response to treatment in chronic inflammatory demyelinating polyradiculoneuropathy.
    Chan YC; Allen DC; Fialho D; Mills KR; Hughes RA
    J Neurol Neurosurg Psychiatry; 2006 Jan; 77(1):114-6. PubMed ID: 16361609
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of IVIG in CIDP: Combined data of the PRIMA and PATH studies.
    Merkies ISJ; van Schaik IN; Léger JM; Bril V; van Geloven N; Hartung HP; Lewis RA; Sobue G; Lawo JP; Durn BL; Cornblath DR; De Bleecker JL; Sommer C; Robberecht W; Saarela M; Kamienowski J; Stelmasiak Z; Tackenberg B; Mielke O;
    J Peripher Nerv Syst; 2019 Mar; 24(1):48-55. PubMed ID: 30672091
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Increased muscle echointensity correlates with clinical disability and muscle strength in chronic inflammatory demyelinating polyneuropathy.
    Fisse AL; Fiegert S; Stoykova Z; Brünger J; Athanasopoulos D; Grüter T; Motte J; Gold R; Pitarokoili K
    Eur J Neurol; 2021 May; 28(5):1698-1705. PubMed ID: 33404183
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical characteristics, and impairment and disability scale scores for different CIDP Disease Activity Status classes.
    Alabdali M; Abraham A; Alsulaiman A; Breiner A; Barnett C; Katzberg HD; Lovblom LE; Perkins BA; Bril V
    J Neurol Sci; 2017 Jan; 372():223-227. PubMed ID: 28017218
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Manual push technique, an alternative route of subcutaneous immunoglobulin administration in chronic inflammatory demyelinating polyradiculoneuropathy: A proof-of-concept study.
    Cocito D; Peci E; Rigaldo S; Canavese C; Migliaretti G; Cossa FM
    Clin Neurol Neurosurg; 2020 Nov; 198():106240. PubMed ID: 32971302
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.